Displaying drugs 2651 - 2675 of 4366 in total
SOT-107
SOT-107 is a drug that is a combination of a protein called transferrin and a poison called diphtheria toxin. This drug treat for a type of brain cancer called a high grade glioma brain tumour. About half of all brain tumours are gliomas.
Investigational
ATL-104
ATL-104 is a potent mitogen for epithelial cells of the gastrointestinal tract. In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents.
Investigational
EVT-101
Investigational
CI-1040
CI-1040 has been used in trials studying the treatment of Lung Cancer, Breast Cancer, Breast Neoplasms, Pancreatic Cancer, and Colorectal Cancer, among others.
Investigational
WP-1066
WP1066 has been used in trials studying the treatment of Melanoma, Brain Cancer, Solid Tumors, and Central Nervous System Neoplasms.
Investigational
MK-1064
MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)).
Investigational
TZP-102
TZP-102 is under investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis).
Investigational
AIM-102
AIM-102 is under investigation in clinical trial NCT01501942 (Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma).
Investigational
PHI-101
Investigational
GCS-100
Investigational
NZ-1002
Investigational
OCU-100
Investigational
PTX-100
Investigational
LX-1004
Investigational
CAN-106
CAN-106 a novel, long-acting monoclonal antibody directed against human complement C5.
Investigational
AVB-101
AVB-101 is a recombinant AAV9 vector encoding the human progranulin (PGRN) gene.
Investigational
Metandienone
Metandienone is an orally active anabolic androgenic steroid. It was introduced to the market in the 1960s but later discontinued and withdrawn from the market. Although it is prohibited in and outside competition by the World Anti-Doping Agency, metandienone continues to be marketed and misused as a performance-enhancing drug in...
Experimental
Withdrawn
Matched Iupac: … -hydroxy-1,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7- …
Matched Products: … เมเทน 10 ... METHAN 10 ... ไดอาบอล - 10 …
Matched Products: … เมเทน 10 ... METHAN 10 ... ไดอาบอล - 10 …
Efonidipine
Efonidipine is a calcium channel blocker of the dihydropyridine class, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, Landel. The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis...
Experimental
ONCOS-102
Investigational
LLL-3348
The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.
Investigational
WL-1002
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
BL-1020
BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
Investigational
Displaying drugs 2651 - 2675 of 4366 in total